Pegetron prospective Optimal Weight-based dosing Response program
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2016
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms POWeR
- Sponsors Schering Canada
- 06 Feb 2016 Results (post hoc pooled analysis of PoWer and RediPEN studies) published in the European Journal of Clinical Microbiology and Infectious Diseases (n = 1242).
- 02 Nov 2010 Results reported at AASLD, according to a Biolex Therapeutics media release.
- 02 Nov 2009 Results have been presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.